Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome
Author:
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Biomedical Engineering,Biomaterials,Biochemistry
Link
http://link.springer.com/content/pdf/10.1007/s11596-007-0208-9.pdf
Reference7 articles.
1. Stone G W, Moliterno D J, Bertrand M et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein llb/llla inhibitors in patients undergoing coronary stenting: The TARGET Trial. Circulation, 2002;105(20):2347–2354
2. Crouch M A, Nappi J M, Cheang K I. Glycoprotein llb/llla receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother, 2003,37:860–875
3. Kim J H, Jeong M H, Rhew J Y et al. Long-term clinical outcomes of platelet glycoprotein llb/llla inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Circ J, 2005,69(2):159–164
4. The RESTORE investigators. Effects of platelet glycoprotein llb/llla blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997;96(5):1445–1453
5. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein llb/llla receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med, 1998, 338(21):1488–1497
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke;Journal of Stroke and Cerebrovascular Diseases;2019-04
2. Protective effects of tirofiban on ischemia/reperfusion-induced renal injury in vivo and in vitro;European Journal of Pharmacology;2015-08
3. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis;Current Medical Research and Opinion;2012-01-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3